Shoshana Eisenstein, NP
Family · Port Clinton, OHNPI 1861620973
Payments from drug & device makers
Across 325 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$941
- AbbVie$800
- Astellas Pharma US Inc$512
- Corcept Therapeutics$500
- Amgen$430
- Novo Nordisk$396
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,24494%
- Education$3326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $941 |
| AbbVie | 55 | $800 |
| Astellas Pharma US Inc | 20 | $512 |
| Corcept Therapeutics | 28 | $500 |
| Amgen | 36 | $430 |
| Novo Nordisk | 24 | $396 |
| Lilly USA, LLC | 17 | $302 |
| GSK | 16 | $251 |
| Amarin Pharma, Inc. | 11 | $148 |
| Abbott | 7 | $141 |
| Sumitomo Pharma America, Inc. | 6 | $124 |
| Pfizer | 7 | $115 |
| Phathom Pharmaceuticals, Inc. | 4 | $83 |
| Merck | 5 | $81 |
| Exact Sciences | 3 | $73 |
| Bayer | 4 | $72 |
| Eisai Inc. | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 5 | $68 |
| Johnson & Johnson | 4 | $64 |
| Acella Pharmaceuticals, LLC | 3 | $51 |
| Tolmar, Inc. | 2 | $48 |
| Sanofi | 1 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$5,576 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $101,215 |
| OzempicSemaglutide | 42 | $86,201 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $44,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $42,049 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $29,816 |
| JanuviaSitagliptin Phosphate | 24 | $25,646 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $24,923 |
| MounjaroTirzepatide | 16 | $24,879 |
| XareltoRivaroxaban | 22 | $24,084 |
| MyrbetriqMirabegron | 23 | $20,047 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $18,654 |
| FarxigaDapagliflozin Propanediol | 14 | $14,855 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,289 |
| Potassium Chloride | 51 | $2,251 |
| Levothyroxine Sodium | 251 | $2,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $101,21569 claims |
| Novo NordiskOzempic | $396 | $86,20142 claims |
| MerckJanumet Xr, Januvia, Janumet | $81 | $74,11660 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $251 | $51,33862 claims |
| Lilly USA, LLCMounjaro | $302 | $24,87916 claims |
| Johnson & JohnsonXarelto | $64 | $24,08422 claims |
| Astellas Pharma US IncMyrbetriq | $512 | $20,04723 claims |
| AstraZenecaFarxiga | $941 | $14,85514 claims |
| AbbVieSynthroid | $800 | $1,09449 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $51 | $85321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Port Clinton
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.